GSK 649868

Drug Profile

GSK 649868

Alternative Names: GSK649868; GW649868; orexin-antagonist; SB-649868

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; Human Genome Sciences
  • Developer GlaxoSmithKline
  • Class Amides; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Orexin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Sleep disorders

Most Recent Events

  • 03 Aug 2012 GlaxoSmithKline acquires Human Genome Sciences
  • 20 Aug 2009 Pharmacokinetics and pharmacodynamics data from animal studies in sleep disorders presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)
  • 31 Jan 2007 Phase-I clinical trials in Sleep disorders in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top